Key Approaches to Managing Protocol Complexity in Oncology Clinical Trials

Early phase oncology trials are becoming more complex as sponsors face growing pressure to optimize dose selection, identify the right patients, generate stronger evidence and control execution risk — all while moving promising therapies forward. Traditional development models that treat clinical strategy, operations and data as separate functions are increasingly struggling to keep pace.

This playbook explores four strategic levers for managing that complexity: integrated clinical and regulatory strategy, biomarker-driven trial design, operational execution and connected data and AI. Learn how bringing these capabilities together earlier can help sponsors reduce uncertainty, improve trial execution and make more confident development decisions.